



Essai Clinique

Généré le 08 mai 2024 à partir de

Titre	Phase III Study of Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive, First-line Metastatic Breast Cancer
Protocole ID	DESTINY-Breast09
ClinicalTrials.gov ID	NCT04784715
Type(s) de cancer	Sein
Phase	Phase III
Type étude	Clinique
Médicament	Deruxtecan (T-DXd) avec ou sans pertuzumab versus taxane, trastuzumab et pertuzumab
Institution	CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL
Ville	
Investigateur principal	Dr Jean-Pierre Ayoub
Coordonnateur	Ana Lydia Tkalec 514-890-8000 poste 14186
Statut	Fermé
But étude	The study will evaluate the efficacy and safety of trastuzumab deruxtecan (also known as T-DXd, DS-8201a), either alone or in combination with pertuzumab, in treating patients with Human epidermal growth factor receptor 2 (HER2)-positive breast cancer as a first line of treatment.
Critères d'éligibilité	<ul style="list-style-type: none">• Patients must be ≥ 18 years of age• Pathologically documented breast cancer that:<ol style="list-style-type: none">1. is advanced or metastatic2. is locally assessed and prospectively centrally confirmed as HER2-positive (IHC3+ or ISH+)3. is documented by local testing as hormone receptor (HR)-positive or HR-negative disease in the metastatic setting• No prior chemotherapy or HER2-targeted therapy for advanced or metastatic breast cancer or only 1 previous line of endocrine therapy in the metastatic setting. Participants who have received chemotherapy or HER2-targeted therapy in the neo-adjuvant or adjuvant setting are eligible if > 6 months from treatment to metastatic diagnosis.• Has protocol-defined adequate organ and bone marrow function
Critères d'exclusion	<ul style="list-style-type: none">• Ineligible for any of the agents on the study.• Any substance abuse or other medical conditions that, in the investigator's opinion, may interfere with subject's participation or study results• Patients with spinal cord compression or clinically active central nervous system metastases. Participants with clinically inactive brain metastases or treated brain metastases that are no longer symptomatic may be included in the study.• Active or prior documented interstitial lung disease (ILD)/pneumonitis or suspected ILD/pneumonitis that cannot be ruled out by imaging at screening• Prior randomization or treatment in a previous trastuzumab deruxtecan study regardless of treatment arm assignment